Australian Capital Territory
Emergencies (Service Provider) Approval 2018 (No 3)
Notifiable instrument NI2018–270
made under the  
Emergencies Act 2004, s62 (Decision about approval)

1	Name of instrument
This instrument is the Emergencies (Service Provider) Approval 2018 (No 3).
2	Commencement 
This instrument commences on 31 May 2018.
3	Approval
I approve Motorsport Safety and Rescue Pty Ltd (the approved provider) to provide ambulance services (the services) at events in the ACT.
4	Conditions
I impose the conditions in Schedule 1 on the approval.
5	Expiry
This instrument expires on 30 May 2019.
Mick Gentleman MLA
Minister for Police and Emergency Services
18 May 2018
SCHEDULE 1

CONDITIONS OF APPROVAL

1.	The approved provider must comply with all conditions set out in the Application for Approval to Provide Ambulance Services in the ACT – AF2015-140. 

2.	The approved provider must seek agreement from the Chief Officer of ACT Ambulance Service prior to providing services. The approved provider must notify the Chief Officer seven calendar days prior to any event at which the approved provider is proposing to provide the services where the event was not specified in the application for approval. 

3.	This instrument approves only the staff nominated in the approved provider’s application for approval under Section 61 of the Emergencies Act 2004.

4.	Staff of the approved provider who are not nominated in the original application may only provide services after the details of those staff and their relevant industry registration are provided in writing to the Chief Officer of ACT Ambulance Service.  The approved provider is responsible for ensuring that all staff comply with all requirements associated with any applicable industry registration.

5.	The approved provider must provide the Chief Officer of ACT Ambulance Service with copies of any updated or renewed insurance documentation if insurance is renewed during the approval period.

6.	The approved provider must give the Chief Officer of ACT Ambulance Service copies of any clinical or pharmaceutical management guidelines implemented or amended during the approval period.